-
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Intelligent Non-invasive Diagnosis of Aneuploidy: Raw Values and Highly Imbalanced Dataset.
Neocleous A, Nicolaides K, Schizas C.
IEEE J Biomed Health Inform 2017;21:1271-1279. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
First trimester maternal serum AFP and total hCG in aneuploidies other than trisomy 21.
Spencer K, Heath V, Flack N, Ong C, Nicolaides KH.
Prenat Diagn 2000;20:635-9.